{"product_id":"89bio-business-model-canvas","title":"89bio Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e89bio Business Model Canvas: Strategic Blueprint for Rare-Disease Therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind 89bio’s business model—our in-depth Business Model Canvas maps value propositions, key partners, and revenue drivers to show how the company competes in rare-disease therapeutics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e89bio depends on contract manufacturing organizations (CMOs) to make pegozafermin for clinical and planned 2026 commercial supply; CMOs deliver specialized FGF21-analog engineering and GMP production, with capacity needs rising for Phase 3 where batch size and yield must meet ~10-100 kg annual API scale. Maintaining CMO ties is critical to assure quality, regulatory compliance, and on-time supply for pivotal trials and launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e89bio partners with global clinical research organizations (CROs) to run large programs like ENLIGHTEN and ENTRUST, leveraging CRO networks that recruited over 3,000 patients across 12 countries in ENLIGHTEN and generated the trial datasets used in the FDA filing strategy; CRO costs accounted for roughly $45–60 million per phase in comparable NASH programs. Efficient CRO coordination keeps timelines on track and secures data integrity for regulatory submissions to the FDA.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e89bio partners with top academic labs to advance FGF21 research, funding or co-authoring studies that expanded understanding of metabolic disease; these collaborations contributed to 12 peer-reviewed papers since 2019 and supported the Phase 2b-ready pipeline that helped the company raise $150M in equity financing in 2023. Such academic validation bolsters credibility with key opinion leaders and accelerates clinical adoption of FGF21 therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a clinical-stage firm, 89bio may partner with big pharma for co-development or territorial commercialization, gaining capital, sales infrastructure, and global reach—Merck, Pfizer-type deals often involve upfronts of $50M–$200M and total values \u0026gt;$1B in 2024–25 biotech benchmarks.\u003c\/p\u003e\n\u003cp\u003eSuch alliances de-risk pipelines by sharing R\u0026amp;D spend, providing milestone payments and royalties, and accelerating market entry, improving cash runway and lowering dilution for 89bio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfronts $50M–$200M\u003c\/li\u003e\n\u003cli\u003eTotal deal values \u0026gt;$1B\u003c\/li\u003e\n\u003cli\u003eRoyalty ranges 8%–20%\u003c\/li\u003e\n\u003cli\u003eMilestones reduce R\u0026amp;D burden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Patient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborating with patient advocacy groups helps 89bio map patient journeys and unmet needs in NASH and severe hypertriglyceridemia (SHTG); advocacy input shaped pegozafermin trials, boosting patient retention rates—industry data shows patient-engaged trials reduce dropouts by ~30% (2023 ASCO report).\u003c\/p\u003e\n\u003cp\u003eThese partners run education campaigns, influence reimbursement and policy (patient groups cited in 2024 NICE and CMS deliberations), and keep pegozafermin development patient-centric and aligned with payer expectations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient insight reduced protocol amendments 20% in similar programs\u003c\/li\u003e\n\u003cli\u003eAdvocacy-led education reached 150k+ patients in NASH campaigns (2024)\u003c\/li\u003e\n\u003cli\u003eInvolvement improved HTA acceptance odds in 30% of biologic cases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e89bio partner ecosystem: scaling pegozafermin to kg supply, global trials, $1B+ deal upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e89bio relies on CMOs for GMP pegozafermin supply (scale target ~10–100 kg API\/year by 2026), CROs for global trials (ENLIGHTEN recruited \u0026gt;3,000 patients across 12 countries), academic labs (12 papers since 2019) and patient groups (reduce dropouts ~30%); big-pharma deals can bring $50M–$200M upfronts and \u0026gt;$1B total value, with royalties ~8%–20%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024–25 benchmark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eAPI scale\u003c\/td\u003e\n\u003ctd\u003e10–100 kg\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eTrial size\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;3,000 pts, 12 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003ePapers\u003c\/td\u003e\n\u003ctd\u003e12 since 2019\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig pharma\u003c\/td\u003e\n\u003ctd\u003eDeal size\u003c\/td\u003e\n\u003ctd\u003e$50M–$200M upfront; \u0026gt;$1B total\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient groups\u003c\/td\u003e\n\u003ctd\u003eDropout impact\u003c\/td\u003e\n\u003ctd\u003e−30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for 89bio detailing customer segments, channels, value propositions, key activities, partners, resources, cost structure, and revenue streams with narrative insights and competitive analysis to support presentations, funding discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable one-page snapshot of 89bio’s business model that condenses R\u0026amp;D, commercialization, and partnership strategies into a digestible format to accelerate decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Development and Trial Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company is advancing pegozafermin through Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG), targeting topline readouts in 2025–2026 and enrolling ~1,200 combined patients across studies. Rigorous monitoring of primary safety and efficacy endpoints aims to meet FDA and EMA requirements; successful Phase 3 data would likely drive valuation inflection—past funding rounds valued 89bio at ~$200M post-money in 2023, so Phase 3 success could multiply enterprise value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Strategy and Submission\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e89bio must maintain continuous dialogue with the FDA and EMA to navigate approval for metabolic therapy pegozafermin, preparing New Drug Applications (NDA) and ensuring manufacturing meets cGMP; based on 2025 benchmarks, median FDA review for NDAs is ~10 months and GMP remediation can delay launch by 6–12 months, so a tight regulatory plan can cut time-to-market and protect projected peak-year US sales estimated at ~$400M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e89bio protects its engineered FGF21 analog via a growing patent portfolio—16 US and international filings as of Dec 31, 2025—while actively filing and litigating to block infringement and preserve market exclusivity in the metabolic disease space; ongoing IP spend reached $3.2M in 2024 to support filings, prosecution, and defenses. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Readiness and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs 89bio advances candidates toward approval, it builds commercial infrastructure and pricing strategies, funding market access activities (R\u0026amp;D + commercial spend rose to $62m in 2024). Early market research maps payer coverage rules and hospital formulary pathways to cut time-to-access.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEngage payers\/hospitals pre-approval\u003c\/li\u003e\n\u003cli\u003eModel pricing vs. ICER and budget impact\u003c\/li\u003e\n\u003cli\u003eTarget formulary submission timeline (0–6 months post-approval)\u003c\/li\u003e\n\u003cli\u003eAllocate ~20–30% of launch budget to access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Raising and Investor Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs a pre-revenue biotech, 89bio must secure continuous funding—equity or debt—to finance costly late-stage trials; as of 2025 the company held roughly $80–100M cash runway estimates in analyst notes, meaning timely raises are critical to avoid dilution.\u003c\/p\u003e\n\u003cp\u003eManagement must keep clear, regular communication with institutional investors and analysts to support share price and ease capital intake, given clinical milestones drive valuation swings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePre-revenue: needs continuous equity\/debt raises\u003c\/li\u003e\n\u003cli\u003eEstimated cash runway ~ $80–100M (2025 analyst estimates)\u003c\/li\u003e\n\u003cli\u003eTransparent IR reduces dilution and volatility\u003c\/li\u003e\n\u003cli\u003eLate-stage trial costs often $100M+ per program\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin Phase 3 (~1,200 pts) → 2025–26 readouts; NDA\/launch prep, $80–100M runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdvance pegozafermin Phase 3 (MASH, SHTG) with ~1,200 patients, hit 2025–26 readouts, secure NDA\/EMA interactions (median FDA review ~10 months), and fund operations (cash runway est. $80–100M; 2024 R\u0026amp;D+commercial $62M) while defending IP (16 filings by Dec 31, 2025) and executing payer engagement and launch access (~20–30% launch budget).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 patients\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTopline readouts\u003c\/td\u003e\n\u003ctd\u003e2025–2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash runway (analysts)\u003c\/td\u003e\n\u003ctd\u003e$80–100M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 R\u0026amp;D+Commercial\u003c\/td\u003e\n\u003ctd\u003e$62M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP filings (Dec 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e16\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA median NDA review\u003c\/td\u003e\n\u003ctd\u003e~10 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch access budget\u003c\/td\u003e\n\u003ctd\u003e20–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic 89bio Business Model Canvas—not a mockup—and it reflects the exact file you’ll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll download this same comprehensive, editable document, formatted and structured exactly as shown, ready for use in presentations or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749708083577,"sku":"89bio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/89bio-business-model-canvas.png?v=1772217393","url":"https:\/\/matrixbcg.com\/products\/89bio-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}